Clinical Trial

Study of GP681 Tablets Compared With Placebo in Patients With Influenza at High Risk of Influenza Complications

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated December 4, 2024 (before its estimated December 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study will evaluate the efficacy, safety, and population pharmacokinetics of a single, oral dose of GP681 compared with placebo in patients aged 12 and older With Influenza at High Risk of Influenza Complications.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-08-25; most recent amendment 2024-12-01.
Status change: Not Yet Recruiting → Recruiting 2024-12-01
Trial Details
NCT Number NCT06573008
Lead Sponsor Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Conditions Influenza, Human
Enrollment 328 participants
Start Date 2024-11-11
Primary Completion 2025-12-30 (estimated)
Study Completion 2025-12-30 (estimated)
Updated on ClinicalTrials.gov 2024-12-04